Article info
PDFReview
Paraneoplastic neurological syndromes: a practical approach to diagnosis and management
- Correspondence to Prof Sarosh R Irani, Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford University, Oxford OX3 9DS, UK; sarosh.irani{at}ndcn.ox.ac.uk
Citation
Paraneoplastic neurological syndromes: a practical approach to diagnosis and management
Publication history
- Accepted July 15, 2021
- First published September 11, 2021.
Online issue publication
January 20, 2022
Article Versions
- Previous version (20 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Which antibody and which cancer in which paraneoplastic syndromes?
- Republished: Which antibody and which cancer in which paraneoplastic syndromes?
- Recommended diagnostic criteria for paraneoplastic neurological syndromes
- Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition
- Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage
- Delayed onset of a second paraneoplastic neurological syndrome in eight patients
- Rhombencephalomyelitis due to possible paraneoplastic syndrome associated with Hodgkin’s lymphoma
- Paraneoplastic encephalopathy: an unusual presenting feature of bladder cancer metastasis
- Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer
- Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone